Sai Life Sciences is into Healthcare & Pharmaceuticals Lifesciences sector and is looking raise funds through Fresh Issue and Offer For Sale
IPO Summary
Sai Life Sciences IPO is a public offering of shares by Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytreyi, Sai Quest Syn Private Limited, Marigold Partners, Sunflower Partners, Tulip Partners and Lily Partners.. The IPO will open on December 11 and will close on December 13. The price band is ₹522 to ₹549 per share and the lot size is 27 shares. The issue size is ₹3,042.62 crore. The shares are expected to be listed on NSE, BSE on December 18 (^). Some additional information that you may find useful are: Share of revenues from Contract Development and Manufacturing/Contract Research is at 66.2%/33.8% in FY24 (v/s 61.0%/39.0% in FY23): (**) - based on higher price band (^) indicative datePromoters of the company are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytreyi, Sai Quest Syn Private Limited, Marigold Partners, Sunflower Partners, Tulip Partners and Lily Partners. Currently promoters hold 41.82% stake in the company. While post-equity promoters stake will be 35.24%
- Company aims to raise between Rs 2,940 to 3,043 crs through this IPO.
- The net proceeds of the issue will be utilized to 1) Rs 600 cr towards debt repayment / pre-payment and 2) General corporate purpose
- Anchor bidding is expected to commence one day prior to the IPO dates. Tentative anchor bidding date would be 10-Dec-24.
- Price band for the IPO has been fixed at Rs 522 to 549 per share and bid lot are in multiple of 27 shares. The implied market cap post-issue at Rs 10,904 to 11,419 crs.
- As per the tentative schedule, allotment date of this IPO is most likely on December 16 and share are expected to be listed on NSE, BSE on December 18.
- Company has direct peer competition in India'a Pharma space. In Listed space peers include DIVI's Laboratories, Suven Pharma, Syngene International amongst others.
- Kotak Mahindra Capital, IIFL Capital, Jefferies India, Morgan Stanley has been appointed as Merchant Banker to the issue. KFin Technologies Ltd. has been appointed as official registrar of the issue.
- Company has not undertaken Pre-IPO placement.
Key Pointers of Sai Life Sciences IPO:
| Sai Life Sciences Limited IPO Snapshot | UdhyamPitch on X | |||
|---|---|---|---|
| Established | City | Sector | Sub-Sector |
| 1999 | Hyderabad | Healthcare & Pharmaceuticals | Lifesciences |
| Issue | Issue Type | Tentative Listing Date | Listing at |
| IPO (Fresh+OFS) | Book Building | 18-Dec-24 | NSE, BSE |
| IPO Dates | Price Band (Rs/sh) | Face Value (Rs/sh) | Min Lot Qty |
| 11-Dec-24 to 13-Dec-24 | ₹ 522 to 549 per sh | ₹ 1 per sh | 27 sh and in multiples |
| Retail App (min) | Retail App (max) | Non-Retail (Rs2-10L App) | Non-Retail (>Rs10L min App) |
| 27 shares ₹ 14,823 | 351 shares up to ₹ 192,699 | 378 to 1,809 shares ₹ 207,522 to 993,141 | 1,836 shares and above ₹ 1,007,964 and above |
There are highly chances of variation in data. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
About Sai Life Sciences Limited
Established in 1999, Sai Life Sciences is innovator-focused CRDMO and provide end-to-end services across the drug discovery, development and manufacturing value chain, for small molecule NCE to global pharmaceutical innovators companies and biotechnology firms. It possess both (a) discovery / contract research and (b) CMC / CDMO capabilities.
Share of revenues from Contract Development and Manufacturing/Contract Research is at 66.2%/33.8% in FY24 (v/s 61.0%/39.0% in FY23)
About Industry
The global small molecule CRDMO industry size is expected to expand at a CAGR of 7.0% from 2023-2028. The global small molecule CRDMO industry is expected to reach USD159 billion by 2028F, comprising c.53% of the overall CRDMO industry globally. Key drivers for this growth are increasing pharmaceutical and biotech R&D outsourcing, continued demand for small molecules, and growing demand for cost-effective drugs. (Source: F&S Report). India's CRDMO market has undergone significant expansion in recent years. The India CRDMO market was amongst the fastest growing markets in APAC over 2018-2023. This growth is expected to continue, with Indian market projected to grow by 14.0% between 2023 and 2028, faster than the growth of the APAC market and the global CRDMO market, reaching an estimated value of USD14.1 billion in 2028.
| Sai Life Sciences Limited IPO Dates | UdhyamPitch on X | |
|---|---|
| Anchor Open | 10-Dec-24 |
| IPO Open | 11-Dec-24 |
| IPO Close | 13-Dec-24 |
| Allotment | 16-Dec-24 |
| Credit of Shares | 17-Dec-24 |
| Refund | 17-Dec-24 |
| Listing | 18-Dec-24 |
| Anchor Investor Lockin (50% of Anchor book investment) | |
| Anchor Investor Lockin (Balance 50% of Anchor book investment) | |
Kindly note UPI Mandate deadline is 5:00 pm IST on closing date. To avoid last minute issue, request you to approve UPI mandate before 4:00 pm IST on last day. In case, UPI mandate has not been approved during the prescribed time period, applications are liable to get rejected.
There are highly chances of variation in dates. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
| Sai Life Sciences Limited IPO - Management Details: | |
|---|---|
| Kanumuri Ranga Raju, Chairman | |
| Krishnam Raju Kanumuri, Managing Director & CEO | |
| Sivaramakrishnan Chittor, Chief Financial Officer | |
| Runa Karan, Company Secretary, Compliance Officer and Legal Head | |
Visit DRHP / RHP for more details on Board of Directors and Management details.
| Sai Life Sciences Limited IPO - Details of Offer/Issue Breakup | UdhyamPitch on X | |||||
|---|---|---|---|---|---|
| Category | Quota (%) | No of Shares-Lower | No of Shares-Upper | Value (Rs Cr)-Lower | Value (Rs Cr)-Upper |
| QIB (Incl Anchor) | 50 | NA | 27,710,562 | NA | 1,521.31 |
| Non-Retail (NII) | 15 | NA | 8,313,168 | NA | 456.39 |
| Non-Retail (NII): >Rs10L | NA | 5,542,112 | NA | 304.26 | |
| Non-Retail (NII): Rs2L-Rs10L | NA | 2,771,056 | NA | 152.13 | |
| Retail | 35 | NA | 19,397,393 | NA | 1,064.92 |
| Employee | NA | . | . | ||
| Shareholder | NA | . | . | ||
| NA=Not Available or Not Calculated | Upper= Upper Price Band | Lower=Lower Price Band | |||||
There are highly chances of variation in data. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
| Sai Life Sciences Limited - IPO Registrar & Transfer Agent (RTA): |
|---|
| KFin Technologies Ltd. Selenium, Tower B, Plot No 31 and 32, Financial District, Nanakramguda, Serilingampally HYDERABAD TELANGANA 500032 |
Check IPO Allotment status of Sai Life SciencesIPO:
| Sai Life Sciences Limited - Anchor Lockin Dates and Details | |
|---|---|
| Anchor Investor Lockin (50% of Investment for 30 days) release of | |
| Anchor Investor Lockin (Balance Investment for 90 days) release of | |
Above information is automatically calculated based on estimations. Chances of errors/changes could be possible due to holidays and/or other conditions. Users are requested to Visit BSE, NSE, SEBI for more information or contact the Company/Merchant Banker/RTA for more information.
| Sai Life Sciences Limited - Documents | |
|---|---|
Disclaimer:
Above article only publishes details on the companies and about forthcoming / upcoming IPO' and are solely intended for educational purpose. We don't solicit or invite any interest of user to invest in any of the investment products. Please review DRHP/RHP/Prospectus for more details about the company, fundamentals and other details. Please visit respective sources to verify and know more details about the IPO. SME IPOs can be more volatile due to smaller market capitalization and liquidity. Prices may fluctuate significantly in response to market conditions. We advise users and/or investors to take opinion from certified and SEBI registered experts before taking any investment decisions.
| Source: SEBI, BSE, NSE |
|---|
FAQ
Posts
0 Comments